128.54
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Abbott Laboratories stock is traded at $128.54, with a volume of 6.80M.
It is up +0.71% in the last 24 hours and down -4.20% over the past month.
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
See More
Previous Close:
$127.63
Open:
$127.86
24h Volume:
6.80M
Relative Volume:
1.07
Market Cap:
$223.72B
Revenue:
$43.84B
Net Income/Loss:
$13.94B
P/E Ratio:
16.07
EPS:
7.9979
Net Cash Flow:
$6.78B
1W Performance:
-3.04%
1M Performance:
-4.20%
6M Performance:
-1.86%
1Y Performance:
+9.03%
Abbott Laboratories Stock (ABT) Company Profile
Name
Abbott Laboratories
Sector
Industry
Phone
(224) 667-6100
Address
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
ABT
Abbott Laboratories
|
128.54 | 222.13B | 43.84B | 13.94B | 6.78B | 7.9979 |
![]()
BSX
Boston Scientific Corp
|
99.24 | 144.89B | 18.49B | 2.50B | 3.49B | 1.6801 |
![]()
SYK
Stryker Corp
|
374.42 | 141.17B | 23.82B | 2.92B | 4.02B | 7.5574 |
![]()
MDT
Medtronic Plc
|
95.78 | 121.91B | 34.20B | 4.69B | 5.30B | 3.6218 |
![]()
EW
Edwards Lifesciences Corp
|
74.64 | 42.65B | 5.69B | 1.41B | 577.90M | 6.9828 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Oct-10-25 | Initiated | The Benchmark Company | Buy |
Jul-18-25 | Upgrade | Jefferies | Hold → Buy |
Jun-16-25 | Initiated | Leerink Partners | Market Perform |
Oct-08-24 | Initiated | Oppenheimer | Outperform |
Sep-19-24 | Initiated | Piper Sandler | Overweight |
Jul-30-24 | Downgrade | Edward Jones | Buy → Hold |
May-30-24 | Initiated | Goldman | Buy |
Jul-21-23 | Upgrade | Wolfe Research | Underperform → Peer Perform |
May-30-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Apr-20-23 | Reiterated | Barclays | Overweight |
Apr-20-23 | Reiterated | Bernstein | Outperform |
Apr-20-23 | Reiterated | JP Morgan | Overweight |
Apr-20-23 | Reiterated | Raymond James | Outperform |
Apr-20-23 | Reiterated | UBS | Buy |
Apr-20-23 | Reiterated | Wolfe Research | Underperform |
Mar-29-23 | Initiated | UBS | Buy |
Oct-26-22 | Initiated | Mizuho | Neutral |
Oct-18-22 | Initiated | Barclays | Overweight |
Oct-12-22 | Initiated | Jefferies | Hold |
Jul-06-22 | Initiated | Wolfe Research | Underperform |
Mar-02-22 | Resumed | BofA Securities | Buy |
Jan-27-22 | Reiterated | Credit Suisse | Outperform |
Jan-27-22 | Reiterated | Morgan Stanley | Overweight |
Jan-27-22 | Reiterated | Raymond James | Outperform |
Jan-27-22 | Reiterated | UBS | Buy |
Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
Oct-27-21 | Upgrade | Atlantic Equities | Neutral → Overweight |
Oct-14-21 | Initiated | Redburn | Neutral |
May-25-21 | Initiated | Barclays | Overweight |
Apr-15-21 | Initiated | Atlantic Equities | Neutral |
Jan-28-21 | Upgrade | BTIG Research | Neutral → Buy |
Sep-11-20 | Initiated | Wolfe Research | Outperform |
Jun-01-20 | Downgrade | Goldman | Neutral → Sell |
Mar-05-20 | Initiated | Citigroup | Buy |
Feb-13-20 | Initiated | Goldman | Neutral |
Feb-06-20 | Resumed | BTIG Research | Neutral |
Jan-02-20 | Downgrade | Guggenheim | Buy → Neutral |
Jun-13-19 | Reiterated | BofA/Merrill | Buy |
Feb-07-19 | Reiterated | BofA/Merrill | Buy |
Jan-02-19 | Downgrade | Citigroup | Neutral → Sell |
Nov-30-18 | Upgrade | Goldman | Neutral → Buy |
Oct-16-18 | Initiated | Barclays | Overweight |
Jun-27-18 | Initiated | Bernstein | Outperform |
Jan-30-18 | Reiterated | Citigroup | Neutral |
Jan-25-18 | Reiterated | Stifel | Buy |
Jan-25-18 | Upgrade | William Blair | Mkt Perform → Outperform |
Jan-03-18 | Initiated | Evercore ISI | Outperform |
Jan-02-18 | Upgrade | JP Morgan | Neutral → Overweight |
Jan-02-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
Oct-19-17 | Reiterated | RBC Capital Mkts | Outperform |
Oct-19-17 | Reiterated | Stifel | Buy |
View All
Abbott Laboratories Stock (ABT) Latest News
How Abbott Laboratories stock reacts to job market data2025 Market Outlook & Verified High Yield Trade Plans - Trung tâm Dự báo KTTV quốc gia
What makes Abbott Laboratories stock attractive to growth fundsPortfolio Profit Report & Safe Entry Momentum Tips - Trung tâm Dự báo KTTV quốc gia
Abbott: GLP-1 BeneficiaryDividend Raise May Be Coming (NYSE:ABT) - Seeking Alpha
How Abbott Laboratories stock compares to growth peersMarket Trend Review & Weekly High Return Stock Opportunities - Trung tâm Dự báo KTTV quốc gia
Is Abbott Laboratories (ABL) stock cheap by valuation metricsForecast Cut & Free Reliable Trade Execution Plans - Trung tâm Dự báo KTTV quốc gia
How Abbott Laboratories stock responds to policy changes2025 Earnings Impact & AI Based Buy/Sell Signal Reports - nchmf.gov.vn
Is Abbott Laboratories stock a good choice for value investors2025 Market Overview & Community Trade Idea Sharing - nchmf.gov.vn
Q&A: What cardiologists know and don’t know about pulsed field ablation - Cardiovascular Business
Abbott Laboratories' October Price Plunge Is a Signal to Buy - MSN
Abbott Labs stock price target raised to $158 from $154 at UBS - Investing.com
Abbott Laboratories' October Price Plunge Is A Signal To Buy - Barchart.com
Abbott Laboratories Stock (ABT) Opinions on Q3 2025 Earnings Report - Quiver Quantitative
Can Abbott (ABT) Balance Medical Devices Growth Against Diagnostics Challenges in 2025? - simplywall.st
Abbott Laboratories price pressured by negative technical patternForecast today17-10-2025 - Economies.com
Abbott Laboratories (ABT) Stock forecasts - Yahoo
Is Abbott Laboratories stock a buy in volatile marketsSwing Trade & Free Weekly Watchlist of Top Performers - newser.com
Abbott Eyes Strong US Diabetes Growth In 2026, Diagnostics Recovery As China Headwinds Ease - insights.citeline.com
Analyst See Noise In Q3 P&L, Affirms Abbott's Medtech Strength - Benzinga
These Analysts Revise Their Forecasts On Abbott Following Q3 Results - Benzinga
Abbott Laboratories Keeps Its Cool Despite A Slight Sales Miss - Finimize
Abbott Laboratories Q3 2025 Earnings: Stable Growth Amid Tariff And China Headwinds - Seeking Alpha
Abbott cuts top end of 2025 guidance as tariff threat looms - Modern Healthcare
UBS reiterates Buy rating on Abbott Labs stock amid sustainable MedTech growth - Investing.com India
Barclays Adjusts Abbott Laboratories Price Target to $162 From $159 - MarketScreener
Abbott Labs Q3 2025: Medical Devices Drive 6.9% Sales Growth - Dallas Express
Abbott Labs stock rating reiterated at Buy by Benchmark on strong device sales - Investing.com
A Quick Look at Today's Ratings for Abbott Laboratories(ABT.US), With a Forecast Between $142 to $150 - 富途牛牛
Abbott Laboratories (NYSE:ABT) Q3 2025 Earnings Call Transcript - MSN
Jefferies Adjusts Price Target on Abbott Laboratories to $149 From $145, Maintains Buy Rating - MarketScreener
Bernstein Adjusts Abbott Laboratories Price Target to $150 From $145, Maintains Outperform Rating - MarketScreener
Raymond James Adjusts Abbott Laboratories Price Target to $146 From $141, Maintains Outperform Rating - MarketScreener
Jefferies Adjusts Abbott Laboratories Price Target to $149 From $145, Maintains Buy Rating - MarketScreener
Abbott Labs stock rating reiterated at Outperform by RBC despite mixed results - Investing.com India
Abbott’s strong Q3 medtech performance offset by diagnostic weakness - Medical Device Network
Abbott Labs stock price target raised to $146 by Wells Fargo on Medtech strength - Investing.com India
Jefferies raises Abbott Labs stock price target to $146 on medical device growth - Investing.com
Abbott Laboratories: Strong Growth Prospects and Stable Financial Health Drive Buy Rating - TipRanks
ABT Q3 Deep Dive: Q3 Results in Line with Expectations, Product Pipeline and Market Dynamics Shape Outlook - TradingView
Abbott (ABT) Profit Margin Surge Challenges Bearish Narratives Despite Earnings Decline Forecast - simplywall.st
Abbott Laboratories Reports Strong Q3 2025 Earnings - TipRanks
Abbott (ABT) Margin Surge Reinforces Bullish Narratives Despite Earnings Decline Forecast - Yahoo Finance
Abbott Laboratories’ Earnings Call Highlights Strong Growth - TipRanks
Strong Performance and Future Potential: Buy Rating for Abbott Laboratories - TipRanks
Why Abbott Laboratories (ABT) Stock Is Down Today - The Globe and Mail
S&P Health Giant Skids On Mixed Third-Quarter News - Investor's Business Daily
Abbott Laboratories (ABT) Q3 2025 Earnings Call Transcript - Fortune
Abbott Laboratories (ABT) Q3 2025 Earnings Call Highlights: Strong Organic Growth and Medical ... - Yahoo Finance
Abbott Laboratories (ABT) Stock Forecasts - Yahoo Finance
Gold Gains Over 1%; Abbott Shares Fall After Q3 Results - Benzinga
Abbott Laboratories (ABT) Q3 2025 Earnings Call Highlights: Stro - GuruFocus
Abbott narrows outlook, Australian stocks react to US-China trade - Yahoo Finance
Abbott Laboratories Stock (ABT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):